Hopstem Biotechnology

Hopstem Biotechnology

Private
HangzhouHealthcare & Life Scienceshttp://hopstem.com/

Last Round

Series B

Oct 31, 2021

Total Funding Raised

$55.5M

Company Overview

Hopstem Biotechnology is a biotechnology company that develops induced pluripotent stem cell (iPSC)-derived therapies for central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Revenue Share

AI Layer

Non-AI

Keywords

induced pluripotent stem cellsiPSCschronic stroke treatmentallogeneic cell therapyneural cell therapyoff-the-shelf cell therapystem cell therapystroke recoveryregenerative medicinebrain repairneuroregenerationclinical-stage biotechnologyneurological disordersGMP manufacturingdrug discovery servicesneurotoxicity testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hopstem Biotechnology Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hopstem Biotechnology Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BOct 31, 2021
Series A ExtensionMay 28, 2021
Series A ExtensionDec 1, 2020
Series ADec 24, 2018

Key People

Founding team and executive leadership

D.Phil. Chia-Hua Maggie Ho

Chief Operating Officer

Executive Team

Hopstem Biotechnology Investors

Notable investors and investment history

InvestorRounds
Cybernaut Investment GroupAngel
Longmen CapitalSeries A Extension
Hillhouse InvestmentSeries B
YuanBio Venture CapitalSeries B, Angel, Series A Extension
Daoyuan CapitalSeries A
Empower InvestmentAngel
Lilly Asia VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2025

    Monthly visitors grew 76% MoM, from 136 to 239.

  • Oct 31, 2021

    $40M round led by Hillhouse Investment

Hopstem Biotechnology Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hopstem Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hopstem Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range8
Year Founded2017
Last FundingOct 31, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.